Medical societies and patient advocates together with EHA call for urgent action to make clinical trials less bureaucratic and more patient-centered

Over the last few years, clinical trials have become increasingly difficult and expensive to conduct, due in great measure to the disproportionate volume of bureaucratic demands involved.

Second consultation of EULAR Feedback on the EU Pharmaceuticals Strategy Roadmap

EULAR calls on the European Commission, the other European institutions and the Member States to improve access to affordable pharmaceuticals.

EULAR Press Releases

Read the latest:

- EULAR: Workplace exclusion of people with arthritis compounded by COVID-19

- The EULAR School of Rheumatology wins Awards for excellence in learning

New: EULAR COVID-19 Repositories for patients and clinicians

Find EULAR guidances and useful resources on COVID-19 outbreak to obtain the best possible recommendations and support:

- RMDs and COVID-19 repository for Clinicians

- RMDs and COVID-19 repository for Patients

EULAR Recommendations 2020

Read the latest:

- EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2

- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update

EULAR Feedback on the EU Pharmaceuticals Strategy Roadmap

EULAR welcomes the initiative of the European Commission to modernise and update the existing regulatory framework for pharmaceutical products in the European Union. 

EULAR RheumaMap: Unmet needs in 2020

The RheumaMap has been updated in 2019. Find out about the unmet needs in rheumatology in this latest edition.

The EULAR - COVID-19 Reporting Database for rheumatologists and other clinicians

To report cases of COVID-19 in patients with RMDs